• Deeptech driven solutions for antibody development

    MAbSilico is a deeptech startup - spinoff of CNRS and INRA research team - committed to the fast discovery and development of biomarker and therapeutic antibodies for our biotech customers.

  • Highlights

    Artificial Intelligence, big data and machine learning for antibody

    AI-driven tools

     

    Deep learning and AI based algorithms

    Proprietary method, unique know-how

    From 20 years of proven research (papers & patents)

    Fast data

    Delivery

    Report within 2 weeks

    Secure your

    IP

    Deep characterization for high protection

    Pay as you use

     

    Full ownership and exclusive right for customer

  • Our tools

    We accelerate and secure the development of your antibody at early stage

  • Focus on MAbTope

    MAbTope: define and secure your epitope

  • Team

    Vincent Puard

    CEO

    10 years of international experience in academia and private company working with antibodies

    Anne Poupon

    CTO

    International expert with more than 20 years of research in bioinformatics as PI at CNRS. R&D programs lead to the invention of our tools.

    Astrid Musnier

    Head of biology

    10 years of international research experience in protein-protein interaction technologies.

    Co-inventor of the tools

    Thomas Bourquard

    Head of bioinformatic

    10 years of international research experience bioinformatic (AI, machine learning, big data).

    Co-inventor of the tools

     

  • Scientific and Advisory board

    Samuel Dominique

    Deeptech entreprenor, French tech ambassador

    Nicolas Felix

    Medtech, startup advisor

    Professor Hervé Watier

    Immunologist, LabEx MabImprove coordinator

  • Partners

  • MAbSilico News

    MAbSilico presents its new tools at the 7th Antibody Industrial Symposium. June 2019

     

    The 7th Antibody Industrial Symposium (AIS2019) will be held the 24th and 25th of June 2019 in Tours, France. This congress, jointly organized by the scientific society LabEx MAbImprove and the industrial organization MabDesign, is part of the series of Industrial Symposia organized by MAbImprove since 2013 (Antibodies Biosimilars, MAbDosing, MAbDelivery, Current & Next Generation Antibody Formats, Antibody Drug Conjugates).

     

    Join Us at the #7AIS2019 Congress @congress_ais – 24/25 June – Tours FR. #innovativeapproaches #therapeuticAbs #mAbs #immunotherapy

    MAbSilico presents its tools at the 12th Annual Proteins & Antibodies Congress. April 2019

    At the annual Proteins & Antibodies Congress, MAbSilico will present the in silico tools with our partner Synthelis for antibody development among the best speakers from big pharma, biotechs, academia and technology innovators. Come to discuss about the most exciting breakthroughs for the discovery and development of antibodies..

     

    Come to visit us during our presentation session.

    MAbSilico is supporting the conference "Intelligence Artificielle & Développement des immunothérapies ". April 2019

    This event in Lyon gather the French companies and organization using Artificial Intelligence for the developpment of immunotherapies..

     

    Come to visit us at our booth.

    MAbSilico is happy to announce the release of the scientific paper "MAbTope" in the Journal of Immunoly. October 2018

    Discover our tools MAbTope and how this AI-driven solution can accelerate and secure the intellectual property of you antibodies. Based on the Ab sequence, perform quick and reliable epitope mapping.

     

    Read more about MAbTope.

    MAbSilico presents its technology at the European Antibody Congress. October 2018

    At the European Antibody Congress, MAbSilico will present the in silico methods for antibody development among the best speakers from big pharma, biotechs, academia and technology innovators to discuss the most exciting breakthroughs when it comes to the discovery and development of antibodies.

     

    Come to visit us at the booth or during the poster session.

    MAbSilico and Synthelis sign a commercial agreement to promote a joint service offering. June 2018

    As of June 21, 2018, Synthelis and MAbSilico combine their know-how and thus capitalize on their respective technology in developing a joint offer through a commercial agreement, responding to the needs of their customers.

     

    This offer combines the cutting-edge expertise of two recognized players in their respective domain: MAbSilico with its in silico method to characterize antibodies at their early stage of development and Synthelis, for its cell-free patented technology.

    MAbSilico is talking at the 6th Antibody Industrial Symposium. June 2018

    The 6th Antibody Industrial Symposium 2018 (AIS2018) will be held the 25th and 26th of June 2018 in Montpellier, France. This congress, jointly organized by the scientific society LabEx MAbImprove and the industrial organization MabDesign, is part of the series of Industrial Symposia organized by MAbImprove since 2013 (Antibodies Biosimilars, MAbDosing, MAbDelivery, Current & Next Generation Antibody Formats, Antibody Drug Conjugates).

    MAbSilico is selected to be accelerated at Le Château. March 2018

    Le Château is an accelerating program for early stage startups.

    MAbSilico is talking at the Immunotherapies for Infectious Diseases Congress. December 2017

    The second edition of the Immunotherapies for Infectious Diseases Congress - I4ID, that will be held in Lyon (France) on December 10-11, 2018, this year dedicated to Host-Directed Therapies (HDT) to fight infectious diseases.

    MAbSilico is selected in the top 500 startups at the Hello Tomorrow Global Challenge. October 2017

    The Hello Tomorrow Challenge is the world’s biggest early-stage startup competition for science and deep technology startups. Each year, they identify the best projects of the Challenge to attend the Hello Tomorrow Summit in Paris, an invite-only event bringing together the people that will change the world using science and technology around top investors in each sector, industrial leaders (Airbus, Google[x], Carrefour, Merck, Air Liquide, Facebook, etc.), international media (Bloomberg, BBC, Wired, etc.) and influencers (in 2016, Mike Bloomberg, Emmanuel Macron, CTO of Meta, CEO of Unity Biotech, etc).

    MAbSilico is at the Next-Generation Antibodies and Protein Analysis. October 2017

    Catalyzed by VIB’s Technology Scouting team, the Tools and Technologies meetings focus on the front end of innovation and bring together key innovators in selected life sciences research fields. The Next-Generation Antibodies and Protein Analysis conference, in Ghent (Belgium), is set to make another world class meeting, bringing together an exciting selection of top speakers and newly emerged companies. In addition to great scientific and technology program, the conference will provide ample networking opportunities.

    MAbSilico received the "Bourse French Tech" from Bpifrance. October 2017

    MAbSilico is founded. September 2017

    We are happy to announce the incorporation of MAbSilico.

  • Contact Us

    Learn more about our tools today.

    INRA Centre Val de loire